{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:41Z","timestamp":1790960561096,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2023-6-27"],"award-info":[{"award-number":["320.6750.2023-6-27"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2023-6-27"],"award-info":[{"award-number":["320.6750.2023-6-27"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2023-6-27"],"award-info":[{"award-number":["320.6750.2023-6-27"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"crossref","award":["320.6750.2023-6-27"],"award-info":[{"award-number":["320.6750.2023-6-27"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75271-x","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:01:51Z","timestamp":1728550911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors"],"prefix":"10.1038","volume":"14","author":[{"given":"Diwei","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"75271_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar, V. et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol. 8, 49. https:\/\/doi.org\/10.3389\/fphar.2017.00049 (2017).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"75271_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4(12), 1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923 (2018).","journal-title":"JAMA Oncol."},{"key":"75271_CR3","unstructured":"NCCN Clinical Practice. Guidelines in management of immunotherapy-related toxicities (Version 1.2024). nccn.org."},{"key":"75271_CR4","doi-asserted-by":"publisher","unstructured":"Moore, D. C. et al. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system. Int Immunopharmacol. 110, 109015. (2022). https:\/\/doi.org\/10.1016\/j.intimp. 109015 (2022).","DOI":"10.1016\/j.intimp"},{"issue":"5","key":"75271_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","volume":"71","author":"TC Haddad","year":"2022","unstructured":"Haddad, T. C. et al. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol. Immunother. 71(5), 1157\u20131165. https:\/\/doi.org\/10.1007\/s00262-021-03068-2 (2022).","journal-title":"Cancer Immunol. Immunother"},{"issue":"3","key":"75271_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","volume":"43","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS Data in the past 15 years. Oncol. Res. Treat. 43(3), 96\u2013102. https:\/\/doi.org\/10.1159\/000505376 (2020).","journal-title":"Oncol. Res. Treat."},{"issue":"1","key":"75271_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S. et al. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 45(1), 65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"75271_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.6004\/jadpro.2021.12.4.4","volume":"12","author":"BB Rogers","year":"2021","unstructured":"Rogers, B. B., Zawislak, C. & Wong, V. Management of hematologic adverse events associated with immune checkpoint inhibitors. J. Adv. Pract. Oncol. 12(4), 392\u2013404. https:\/\/doi.org\/10.6004\/jadpro.2021.12.4.4 (2021).","journal-title":"J. Adv. Pract. Oncol."},{"key":"75271_CR9","doi-asserted-by":"publisher","first-page":"9965","DOI":"10.2147\/OTT.S223616","volume":"12","author":"A Kanbour","year":"2019","unstructured":"Kanbour, A. et al. Pancytopenia and limbic encephalopathy complicating immunotherapy for clear cell endometrial cancer with microsatellite instability-high (MSI-H). Onco Targets Ther. 12, 9965\u20139973. https:\/\/doi.org\/10.2147\/OTT.S223616 (2019).","journal-title":"Onco Targets Ther."},{"issue":"3","key":"75271_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/bjh.17387","volume":"193","author":"I Amanam","year":"2021","unstructured":"Amanam, I. et al. Immune thrombocytopenia after immune checkpoint inhibitor therapy. Br. J. Haematol. 193(3), 677\u2013681. https:\/\/doi.org\/10.1111\/bjh.17387 (2021).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"75271_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy, N. et al. Haematological immune-related adverse events Induced by anti-pd-1 or anti-Pd-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 6(1), e48\u201357. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3 (2019).","journal-title":"Lancet Haematol."},{"key":"75271_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel, S. et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur. J. Cancer. 82, 34\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.032 (2017).","journal-title":"Eur. J. Cancer"},{"key":"75271_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli, F. et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur. J. Cancer. 103, 7\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129 (2018).","journal-title":"Eur. J. Cancer"},{"key":"75271_CR14","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","volume":"11","author":"NE Omar","year":"2020","unstructured":"Omar, N. E. et al. Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review. Front. Immunol. 11, 1354. https:\/\/doi.org\/10.3389\/fimmu.2020.01354 (2020).","journal-title":"Front. Immunol."},{"key":"75271_CR15","doi-asserted-by":"publisher","first-page":"790051","DOI":"10.3389\/fimmu.2021.790051","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang, X., NaNa, H. & Lejie, C. Immune thrombocytopenia induced by immune checkpoint inhibitrs in lung cancer: case report and literature review. Front. Immunol. 12, 790051. https:\/\/doi.org\/10.3389\/fimmu.2021.790051 (2021).","journal-title":"Front. Immunol."},{"issue":"8","key":"75271_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13(8), 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"75271_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53 (3), 177\u2013190 (1999).","journal-title":"Am. Stat."},{"issue":"3.4","key":"75271_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2152\/jmi.70.516","volume":"70","author":"S Harada","year":"2023","unstructured":"Harada, S. et al. A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab: case report. J. Med. Invest. 70(3.4), 516\u2013520. https:\/\/doi.org\/10.2152\/jmi.70.516 (2023).","journal-title":"J. Med. Invest."},{"key":"75271_CR19","doi-asserted-by":"publisher","first-page":"100871","DOI":"10.1016\/j.rmcr.2019.100871","volume":"28","author":"H Mori","year":"2019","unstructured":"Mori, H. et al. Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer. Respir Med. Case Rep. 28, 100871. https:\/\/doi.org\/10.1016\/j.rmcr.2019.100871 (2019).","journal-title":"Respir Med. Case Rep."},{"issue":"5","key":"75271_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","volume":"166","author":"SK Quirk","year":"2015","unstructured":"Quirk, S. K., Shure, A. K. & Agrawal, D. K. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 166(5), 412\u2013424. https:\/\/doi.org\/10.1016\/j.trsl.2015.06.005 (2015).","journal-title":"Transl Res."},{"issue":"4","key":"75271_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/1078155221","volume":"28","author":"D Nelson","year":"2022","unstructured":"Nelson, D. et al. Thrombotic thrombocytopenic purpura associated with pembrolizumab. J. Oncol. Pharm. Pract. 28(4), 979\u2013982. https:\/\/doi.org\/10.1177\/1078155221 (2022).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"75271_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","volume":"107","author":"Y Kanjanapan","year":"2019","unstructured":"Kanjanapan, Y. et al. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Eur. J. Cancer. 107, 1\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.017 (2019).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"75271_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/imt-2017-0100","volume":"10","author":"T Jotatsu","year":"2018","unstructured":"Jotatsu, T. et al. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Immunotherapy. 10(2), 85\u201391. https:\/\/doi.org\/10.2217\/imt-2017-0100 (2018).","journal-title":"Immunotherapy"},{"key":"75271_CR24","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","volume":"129","author":"DC Moore","year":"2024","unstructured":"Moore, D. C. et al. PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review. Int. Immunopharmacol. 129, 111606. https:\/\/doi.org\/10.1016\/j.intimp.2024.111606 (2024).","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"75271_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis, E. J. et al. Hematologic complications of immune checkpoint inhibitors. Oncologist. 24(5), 584\u2013588. https:\/\/doi.org\/10.1634\/theoncologist.2018-0574 (2019).","journal-title":"Oncologist"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75271-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75271-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75271-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T13:01:44Z","timestamp":1728824504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75271-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75271-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable. This article does not involve animal or human experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"23699"}}